RADIATION-INDUCED LUNG DAMAGE AFTER THORACIC IRRADIATION FOR HODGKINS-DISEASE - THE ROLE OF FRACTIONATION

被引:58
作者
DUBRAY, B
HENRYAMAR, M
MEERWALDT, JH
NOORDIJK, EM
DIXON, DO
COSSET, JM
THAMES, HD
机构
[1] MD ANDERSON CANC CTR, EORTC LYMPHOMA COOPERAT GRP, HOUSTON, TX USA
[2] MD ANDERSON CANC CTR, DEPT BIOMATH, HOUSTON, TX USA
关键词
LINEAR-QUADRATIC MODEL; RADIATION-INDUCED LUNG TOXICITY; HODGKINS DISEASE;
D O I
10.1016/0167-8140(95)01606-H
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: to estimate the alpha/beta ratio for damage to human lung after thoracic irradiation for Hodgkin's disease. Patients and methods: The criterion for lung injury was the presence of radiological changes in the vicinity of the mediastinum as assessed on regular follow-up chest X-ray examinations. Patients with supradiaphragmatic stage I-II Hodgkin's disease received mantle field irradiation as part of their treatment between 1964 and 1981 (E.O.R.T.C, protocols H1, H2, and 115). The total mediastinal doses fixed by the protocols were 35-40 Gy. The fractional doses were left to the decision of the physicians in charge: the most frequent regimens were 5 x 1.8, 5 x 2.0, 4 x 2.5 and 3 x 3.3 Gy per week. The data were fit to the linear-quadratic (L.Q.) model using time-to-injury as endpoint. Results: 1048 (97%) of 1082 patients were evaluable. The mean follow-up duration was 8 years. One hundred and ninety-five cases of radiologically-visible lung damage were observed after a median interval of 6 months (range: 0-101), The 3-year actuarial probability of lung damage was 19%(95% confidence limits: 17, 21). Multivariate analysis (Cox model, stratified by protocol) showed an increased risk of damage with dose per fraction (relative risk, R.R. = 2.22 per Gy (1.75, 2.82)), the presence of systemic symptoms (R.R. = 1.53 (1.09, 2.15)), and total mediastinal dose (R.R. = 1.06 per Gy (1.01, 1.12)). Age, sex, histological type, number of involved nodal sites and radiotherapy duration did not significantly modify the risk of lung damage. The L.Q. model parameters were: alpha = 0.031 Gy(-1) (0.003, 0.059), beta = 0.010 Gy(-2) (0.007, 0.013), alpha/beta = 3.07 Gy (-0.23, 8.46), Conclusion: this low alpha/beta ratio is consistent with late effects values from animals and humans, and illustrates the influence of large fraction sizes on the occurrence of late pulmonary complications.
引用
收藏
页码:211 / 217
页数:7
相关论文
共 43 条
[1]   NEW OPTIONS IN DIRECT ANALYSIS OF DOSE-RESPONSE DATA [J].
BENTZEN, SM ;
THAMES, HD ;
TUCKER, SL ;
SMITH, C .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1990, 57 (01) :221-225
[2]   INCIDENCE AND LATENCY OF RADIATION REACTIONS [J].
BENTZEN, SM ;
THAMES, HD .
RADIOTHERAPY AND ONCOLOGY, 1989, 14 (03) :261-262
[3]   DIRECT ESTIMATION OF LATENT TIME FOR RADIATION-INJURY IN LATE-RESPONDING NORMAL-TISSUES - GUT, LUNG, AND SPINAL-CORD [J].
BENTZEN, SM ;
THAMES, HD ;
TRAVIS, EL ;
ANG, KK ;
VANDERSCHUEREN, E ;
DEWIT, L ;
DIXON, DO .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1989, 55 (01) :27-43
[4]   DOSE-EFFECT RELATIONS FOR LOCAL FUNCTIONAL AND STRUCTURAL-CHANGES OF THE LUNG AFTER IRRADIATION FOR MALIGNANT-LYMPHOMA [J].
BOERSMA, LJ ;
DAMEN, EMF ;
DEBOER, RW ;
MULLER, SH ;
ROOS, CM ;
OLMOS, RAV ;
VANZANDWIJK, N ;
LEBESQUE, JV .
RADIOTHERAPY AND ONCOLOGY, 1994, 32 (03) :201-209
[5]   A REANALYSIS OF AVAILABLE DOSE-RESPONSE AND TIME-DOSE DATA IN HODGKINS-DISEASE [J].
BRINCKER, H ;
BENTZEN, SM .
RADIOTHERAPY AND ONCOLOGY, 1994, 30 (03) :227-230
[6]   CLINICAL STAGE-I AND HODGKIN STAGE-II DISEASE - A SPECIFICALLY TAILORED THERAPY ACCORDING TO PROGNOSTIC FACTORS [J].
CARDE, P ;
BURGERS, JMV ;
HENRYAMAR, M ;
HAYAT, M ;
SIZOO, W ;
VANDERSCHUEREN, E ;
MONCONDUIT, M ;
NOORDIJK, EM ;
LUSTMANMARECHAL, J ;
TANGUY, A ;
DEPAUW, B ;
COSSET, JM ;
CATTAN, A ;
SCHNEIDER, M ;
THOMAS, J ;
MEERWALDT, JH ;
SOMERS, R ;
TUBIANA, M .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (02) :239-252
[7]  
CARMEL RJ, 1976, CANCER-AM CANCER SOC, V37, P2813, DOI 10.1002/1097-0142(197606)37:6<2813::AID-CNCR2820370637>3.0.CO
[8]  
2-S
[9]   THE EORTC TRIALS FOR LIMITED STAGE HODGKINS-DISEASE [J].
COSSET, JM ;
HENRYAMAR, M ;
MEERWALDT, JH ;
CARDE, P ;
NOORDIJK, EM ;
THOMAS, J ;
BURGERS, JMV ;
SOMERS, R ;
HAYAT, M ;
TUBIANA, M .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (11) :1847-1850
[10]  
COSSET JM, 1992, B CANCER, V79, P610